argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer.
Short Term Liabilities: 1AE's short term assets (€959.9M) exceed its short term liabilities (€102.4M).
Long Term Liabilities: 1AE's short term assets (€959.9M) exceed its long term liabilities (€241.4M).
Debt to Equity History and Analysis
Debt Level: 1AE is debt free.
Reducing Debt: 1AE had no debt 5 years ago.
Balance Sheet
Inventory Level: 1AE has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 1AE's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 1AE has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 1AE is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 68.5% per year.
What is argenx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 1AE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 1AE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1AE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1AE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1AE's dividend in 3 years as they are not forecast to pay a notable one for the German market.
What is the CEO of argenx's salary, the management and board of directors tenure and is there insider trading?
2.7yrs
Average management tenure
CEO
TimVan Hauwermeiren(47yo)
11.4yrs
Tenure
€4,402,768
Compensation
Mr. Tim Van Hauwermeiren, MSc, EMBA, has been the Chief Executive Officer and Executive Director at argenx SE since July 2008 and July 9, 2014 respectively. Mr. Van Hauwermeiren co-founded Argenx SE in 200 ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD4.90M) is above average for companies of similar size in the German market ($USD3.71M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
2.7yrs
Average Tenure
55yo
Average Age
Experienced Management: 1AE's management team is considered experienced (2.7 years average tenure).
Board Age and Tenure
4.6yrs
Average Tenure
59.5yo
Average Age
Experienced Board: 1AE's board of directors are considered experienced (4.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Sell€715,67905 Mar 19
Tim Van Hauwermeiren
Entity
Individual
Role
Chief Executive Officer
CEO & Executive Director
Shares
6,107
Max Price
€117.19
Sell€2,132,35204 Mar 19
Tim Van Hauwermeiren
Entity
Individual
Role
Chief Executive Officer
CEO & Executive Director
Shares
18,205
Max Price
€117.13
Sell€678,40917 Dec 18
Tim Van Hauwermeiren
Entity
Individual
Role
Chief Executive Officer
CEO & Executive Director
Shares
7,370
Max Price
€92.05
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.1%.
Management Team
Eric Castaldi (55yo)
Chief Financial Officer
Tenure: 5.7yrs
Dirk Marcel Beeusaert (55yo)
General Counsel
Tenure: 2.7yrs
Tim Van Hauwermeiren (47yo)
CEO & Executive Director
Tenure: 11.4yrs
Compensation: €4.40m
Hans de Haard (59yo)
Chief Scientific Officer
Tenure: 11.4yrs
Joke Comijn
Director Corporate Communications & Investor Relations (EU)
Tenure: 0yrs
R. Woods (51yo)
Chief Operating Officer
Tenure: 1.7yrs
Wim Parys
Chief Medical Officer
Tenure: 0.9yrs
Arjen Lemmen
Vice President of Corporate Development & Strategy
Tenure: 0.9yrs
Board Members
Don deBethizy (69yo)
Non-Executive Director
Tenure: 4.6yrs
Compensation: €497.40k
Peter K. Verhaeghe (61yo)
Chairman of the Board
Tenure: 5.4yrs
Compensation: €522.40k
Werner Lanthaler (51yo)
Vice-Chairperson
Tenure: 0yrs
Compensation: €499.90k
Tony Rosenberg (66yo)
Non-Executive Director
Tenure: 2.7yrs
Compensation: €487.40k
Pam Klein (58yo)
Non-Executive Director
Tenure: 3.7yrs
Compensation: €487.40k
Tim Van Hauwermeiren (47yo)
CEO & Executive Director
Tenure: 11.4yrs
Compensation: €4.40m
David Lacey (67yo)
Non-Executive Director
Tenure: 5.4yrs
Compensation: €494.90k
James Daly (58yo)
Non-Executive Director
Tenure: 1.6yrs
Compensation: €961.75k
Company Information
argenx SE's company bio, employee growth, exchange listings and data sources
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead product candidates include Efga ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/13 22:39
End of Day Share Price
2019/12/13 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.